We have acquired exclusive rights to commercialise an investigational oral therapy for early-stage Alzheimer’s disease in our key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries.
Read more here.
We have acquired exclusive rights to commercialise an investigational oral therapy for early-stage Alzheimer’s disease in our key markets, including...
For the sixth consecutive year, Acino has achieved Level 1 Broad-Based Black Economic Empowerment (B-BBEE) contributor status in South Africa....
We are proud to share that Acino has been named one of Ukraine’s Top 50 Best Employers for the second...
We are delighted to announce that Acino South Africa has been recognised as a Top Employer for 2025, marking the...
Maryna Larionova joined Acino Ukraine as an Accountant in August 2017, during a transformative period in her life. As a...
Arcera aims to become a global life sciences company, with the purpose of enabling longer and healthier lives while driving...
We use cookies to create statistics that help us to improve the quality of our website and your user experience. By clicking on “Accept All”, you consent to the processing of data by Acino and the transfer of data to third parties. You can also tailor your consent for specific data processing purposes. Once you have made your choice, click on “Confirm”. Find detailed information and modify your preferences at any time in our Privacy Notice.
Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.
We would like to set Google Analytics cookies to help us analyse the traffic on our website.